Nxera Pharma and Shionogi Unveil QUVIVIQ™ In Japan For Insomnia Relief

Nxera Pharma Co., Ltd. (formerly known as Sosei Group or Sosei Heptares) and Shionogi & Co., Ltd. have announced the launch of QUVIVIQ™ (daridorexant) 25 and 50 mg in Japan. This new treatment is now available for adults suffering from insomnia. QUVIVIQ™ is an oral medication that works by targeting specific receptors involved in wakefulness. It helps reduce excessive wakefulness and promotes better sleep by blocking the action of orexin, a neuropeptide that keeps us awake.

Nxera Pharma Japan Co., Ltd., a fully owned subsidiary of Nxera Pharma, holds the approval for QUVIVIQ™ and will help provide the drug. Under a commercial partnership agreement announced on October 1, 2024, Shionogi will manage the distribution and sales of QUVIVIQ™ in Japan. For Nxera, this milestone demonstrates its capability to develop innovative treatments for patients in Japan and strengthens its goal of becoming the preferred partner for companies aiming to develop and market new therapies in the Japanese market.

Shionogi is now focusing on a new area called the 'QOL disease area,' which is less influenced by market trends. With the launch of QUVIVIQ™, Shionogi aims to strengthen this area as an important part of its business. Nxera and Shionogi are working together to make QUVIVIQ™ available as soon as possible, aiming to provide a long-term solution for patients with insomnia.